Cancer Drug Resistance
All Journals
Search Log In
Home Articles Special Topics Volumes Webinars Videos
Cancer Drug Resistance
Search Submit
Home Articles Special Topics Volumes Webinars Videos

Volume

Ferroptosis-related signaling pathways in cancer drug resistance

Ferroptosis-related signaling pathways in cancer drug resistance

Cancer-associated fibroblast-derived extracellular vesicles: regulators and therapeutic targets in the tumor microenvironment

Cancer-associated fibroblast-derived extracellular vesicles: regulators and therapeutic targets in the tumor microenvironment

Integrative multi-omics analysis for identifying novel therapeutic targets and predicting immunotherapy efficacy in lung adenocarcinoma

Integrative multi-omics analysis for identifying novel therapeutic targets and predicting immunotherapy efficacy in lung adenocarcinoma

Regulatory role of non-coding RNAs in 5-Fluorouracil resistance in gastrointestinal cancers

Regulatory role of non-coding RNAs in 5-Fluorouracil resistance in gastrointestinal cancers

Optimizing therapeutic approaches for HR+/HER2- advanced breast cancer: clinical perspectives on biomarkers and treatment strategies post-CDK4/6 inhibitor progression

Optimizing therapeutic approaches for HR+/HER2- advanced breast cancer: clinical perspectives on biomarkers and treatment strategies post-CDK4/6 inhibitor progression

Histone deacetylases in the regulation of cell death and survival mechanisms in resistant BRAF-mutant cancers

Histone deacetylases in the regulation of cell death and survival mechanisms in resistant BRAF-mutant cancers

Metabolic crossroads: unravelling immune cell dynamics in gastrointestinal cancer drug resistance

Metabolic crossroads: unravelling immune cell dynamics in gastrointestinal cancer drug resistance

Exploring YAP1-related TIME in SCLC: implications for survival and treatment response to immuno-chemotherapy

Exploring YAP1-related TIME in SCLC: implications for survival and treatment response to immuno-chemotherapy

Overcoming drug resistance in castrate-resistant prostate cancer: current mechanisms and emerging therapeutic approaches

Overcoming drug resistance in castrate-resistant prostate cancer: current mechanisms and emerging therapeutic approaches

Sophisticated roles of tumor microenvironment in resistance to immune checkpoint blockade therapy in hepatocellular carcinoma

Sophisticated roles of tumor microenvironment in resistance to immune checkpoint blockade therapy in hepatocellular carcinoma

Antibody-drug conjugates in breast cancer treatment: resistance mechanisms and the role of therapeutic sequencing

Antibody-drug conjugates in breast cancer treatment: resistance mechanisms and the role of therapeutic sequencing

The epigenetic mechanisms involved in the treatment resistance of glioblastoma

The epigenetic mechanisms involved in the treatment resistance of glioblastoma

Unraveling <i>BRAF</i> alterations: molecular insights to circumvent therapeutic resistance across cancer types

Unraveling <i>BRAF</i> alterations: molecular insights to circumvent therapeutic resistance across cancer types

Research advances in natural sesquiterpene lactones: overcoming cancer drug resistance through modulation of key signaling pathways

Research advances in natural sesquiterpene lactones: overcoming cancer drug resistance through modulation of key signaling pathways

Strategies to combat cancer drug resistance: focus on copper metabolism and cuproptosis

Circular RNAs modulate cancer drug resistance: advances and challenges

Exosomal miR-92b-5p regulates N4BP1 to enhance PTEN mono-ubiquitination in doxorubicin-resistant AML

Exosomal miR-92b-5p regulates N4BP1 to enhance PTEN mono-ubiquitination in doxorubicin-resistant AML

Circular RNAs modulate cancer drug resistance: advances and challenges

Mechanisms of resistance to NAMPT inhibitors in cancer

Mechanisms of resistance to NAMPT inhibitors in cancer

The genetic architecture of bone metastases: unveiling the role of epigenetic and genetic modifications in drug resistance

Tumor microenvironment-driven resistance to immunotherapy in non-small cell lung cancer: strategies for Cold-to-Hot tumor transformation

Ivosidenib enhances cisplatin sensitivity in ovarian cancer by reducing cancer cell stemness

Unveiling MAGEA3: a novel predictive biomarker for bevacizumab resistance in colorectal cancer

FGFR1 overexpression promotes resistance to PI3K inhibitor alpelisib in luminal breast cancer cells through receptor tyrosine kinase signaling-mediated activation of the estrogen receptor

Advances in the application of patient-derived xenograft models in acute leukemia resistance

FGFR1 overexpression promotes resistance to PI3K inhibitor alpelisib in luminal breast cancer cells through receptor tyrosine kinase signaling-mediated activation of the estrogen receptor

ZEB2 upregulation modulates the polarization of TAMs toward the immunosuppressive state in EGFR-TKI-resistant NSCLC

ZEB2 upregulation modulates the polarization of TAMs toward the immunosuppressive state in EGFR-TKI-resistant NSCLC

PER2 expression and cellular localization play a critical role in tumor aggressiveness and drug resistance in an <i>in vitro</i> model of hepatocellular carcinoma

PER2 expression and cellular localization play a critical role in tumor aggressiveness and drug resistance in an <i>in vitro</i> model of hepatocellular carcinoma

Acquired resistance to molecularly targeted therapies for cancer

Acquired resistance to molecularly targeted therapies for cancer

Fibroblast growth factor receptor alterations and resistance mechanisms in the treatment of pediatric solid tumors

Fibroblast growth factor receptor alterations and resistance mechanisms in the treatment of pediatric solid tumors

Antibody-drug conjugates in breast cancer: current resistance mechanisms and future combination strategies

MicroRNA-mediated autophagy regulation in thyroid cancer drug resistance

Integrated multi-omics profiling of immune microenvironment and drug resistance signatures for precision prognosis in prostate cancer

Modeling methods of different tumor organoids and their application in tumor drug resistance research

Interactions between tumor microenvironment and resistance to transarterial and systemic treatments for HCC

Interactions between tumor microenvironment and resistance to transarterial and systemic treatments for HCC

The next frontier in antibody-drug conjugates: challenges and opportunities in cancer and autoimmune therapy

CF10/LV overcomes acquired resistance to 5-FU/LV in colorectal cancer cells through downregulation of the c-Myc/ABCB5 axis

Decoding breast cancer treatment resistance through genetic, epigenetic, and immune-regulatory mechanisms: from molecular insights to translational perspectives

Super-enhancer inhibitors THZ2 and JQ1 reverse temozolomide resistance in glioblastoma by suppressing SE-driven SOX9 expression

Effects of FAP<sup>+</sup> cancer-associated fibroblasts on anti-PD-1 immunotherapy and CD4<sup>+</sup> T cell polarization in gastric cancer

Lactylation: a novel driver of drug resistance in the tumor microenvironment

Corosolic acid increases the therapeutic effect of cisplatin on gastric cancer by regulating Gpx4-dependent ferroptosis

IRE1α modulates M1 oncolytic virus sensitivity via ER stress regulation in bladder cancer

<i>ROS1</i> mutations promote an immunosuppressive tumor microenvironment via <i>MYC</i> to confer immune evasion in head and neck cancer

New advances in understanding the mechanisms and treatment challenges of ALK-targeted therapy resistance in lung cancer

Resistance signatures manifested in early drug response across cancer types and species

Cryptotanshinone differentially induces cell death in <i>ATP6V0D1</i>-deficient pancreatic cancer cells

Targeting the hypoxia signaling pathway with nanomedicine to reverse immunotherapy resistance

Integrating genomic mutations and tumor-infiltrating lymphocytes improves prediction of response to trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer

Immune checkpoint inhibitors in hepatocellular carcinoma therapy: resistance mechanisms, liver transplantation challenges and management strategies

Distinct adaptive strategies to cisplatin, vinblastine and gemcitabine in a panel of chemoresistant bladder cancer cell lines

Molecular targeting of the deubiquitinase USP14 to circumvent cisplatin resistance in ovarian carcinoma and identification of novel inhibitors

Cisplatin resistance in head and neck squamous cell carcinoma is linked to DNA damage response and cell cycle arrest transcriptomics rather than poor drug uptake

CDK4/6 and BET inhibitors synergistically suppress pancreatic tumor growth and epithelial-to-mesenchymal transition by regulating the GSK3β-mediated Wnt/β-catenin pathway

KLF5 promotes tumor proliferation and oxaliplatin resistance via chromatin remodeling in KRAS-mutated colorectal cancer

Recent progress on tyrosine kinase inhibitors resistance in renal cell carcinoma: another brick in the wall?

Targeting tumor-draining lymph node to overcome resistance to cancer immunotherapy: an update

Circular RNA-based liquid biopsy: a promising approach for monitoring drug resistance in cancer

Novel FAK inhibitors suppress tumor growth and reverse EGFR-TKI resistance in non-small cell lung cancer

Actions for 0 selected articles

Cancer Drug Resistance
ISSN 2578-532X (Online)
Navigation
Follow Us
Navigation

Committee on Publication Ethics

https://members.publicationethics.org/members/cancer-drug-resistance

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/

Committee on Publication Ethics

https://members.publicationethics.org/members/cancer-drug-resistance

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/
Discover Content
Follow OAE
Twitter
Facebook
LinkedIn
YouTube
BiLiBiLi
WeChat
Rss
© 2016-2025 OAE Publishing Inc., except certain content provided by third parties